Patients with rare bone cancer still have low survival rates

Share this content:

the ONA take:

Mesenchymal chondrosarcoma remains classified among the more deadly cancer types, but a recent study has indicated that survival for this disease may not be as low as was previously thought.

A Loyola University Medical Center study, led by senior author Lukas Nystrom, MD, reviewed survival for 205 individuals with mesenchymal chondrosarcoma (cases occurring between 1973 and 2011).

Data was sourced from the Surveillance, Epidemiology and End Results (SEER) program database, which is administered through the National Cancer Institute (NCI). Fifty-one percent survived a minimum of 5 years, and 43 percent survived 10 years or more. survival rates observed differed, depending on the tumor location: an axial location demonstrated a lower survival rate.

Dr. Nystrom has suggested that this lower survival outcome could be attributable to the inoperable location of the axial tumors.

Improved screening techniques and technology could be a factor in the lowering (if still high) mortality rates overall.

First-of-its-kind study shows higher concentration of trace elements in bone cancer
Mesenchymal chondrosarcoma remains classified among the more deadly cancer types.
Ten-year survival has been reported to be as low as 20 percent. But a Loyola University Medical Center study has found survival is not as dismal as prior reports.
READ FULL ARTICLE From Medical Express
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs